AEMD Attracts More Financing
Brian Marckx, CFA
Aethlon Medical (AEMD) continues to attract financing to fund development of their Hemopurifier, reflecting ongoing investor interest. Since the beginning of the current year Aethlon has raised over $1.6 million in new financing, the most recent of which came in mid-June from the sale of 8.22 million shares of common stock at $0.072/share (80% of the most recent avg 5-day closing price) for gross proceeds of $592k. The investor also received seven-year warrants to purchase 4.1 million common shares for $0.109 (120% premium to the most recent avg 5-day closing price).
To access a free copy of the full research report, please visit Brian Marckx's coverage page at scr.zacks.com.Read the Full Research Report on AEMD
More From Zacks.com
- Investment & Company Information
- Aethlon Medical